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Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin disease induced by a complex interaction 
between susceptibility genes encoding skin barrier components and environmental allergen 
exposure that results in type 2 cytokine production. Although genetic lesions in either component 
can be risk factors for disease in patients, whether these pathways interact in the development of 
AD is not clear. To test this, we mated mice with T-cell specific expression of constitutively active 
Stat6 (Stat6VT) that spontaneously develop allergic skin inflammation with Flaky tail (Ft) mice 
that have mutations in Flg and Tmem79 genes that each affect skin barrier function. Our results 
demonstrate that over 90% of the Stat6VT transgenic mice carrying the Ft alleles (Stat6VTxFt−/−) 
develop severe atopic dermatitis lesions by 3-5 months of age, compared with only 40% of 
Stat6VT mice that develop disease by 6-7 months of age. Further, histopathological analysis of 
skin tissues from Stat6VTxFt−/− mice revealed extensive thickening of the dermis with increased 
inflammatory infiltrates as compared with Stat6VT mice. Our study suggests that skin barrier 
defects and altered Th2 responses independently cooperate in the pathogenesis of allergic skin 
inflammation, similar to effects observed in patients with AD.
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INTRODUCTION
Atopic dermatitis (AD) is a chronic inflammatory skin disease that affects 25% of children 
and 1–3 % of adults worldwide [1, 2]. The incidence of AD has increased by 2- to 3- fold 
over the past several decades, especially in industrialized countries. The pathogenesis of AD 
may result from complex interactions between environmental and genetic factors, barrier 
defects and immune dysregulation resulting in epidermal hyperplasia and increased 
penetration of allergens and microbial pathogens [3, 4]. Recent studies have implicated a 
strong association between a defect in the skin barrier and the pathogenesis of AD [5]. The 
defect is caused by genetic loss-of-function mutations in the FLG gene encoding filaggrin, a 
key structural protein required for epidermal barrier function. These mutations are found in a 
substantial proportion of AD patients [6, 7]. Flaky tail mice (Ft) have a mutation in the Flg 
gene similar to mutations seen in patient DNA [8, 9], but also have a second mutation, the 
matted mutation in the Tmem79 gene [10, 11] that is closely linked to Flg on mouse 
chromosome 3. Both mutations contribute to changes in barrier function and mild 
spontaneous dermatitis in these mouse models. Ft or Flg-mutant mice have increased 
susceptibility to allergen sensitization, and have a propensity to develop spontaneous AD-
like lesions, varying with the genetic background [8, 12, 13].
We have previously shown that Stat6VT transgenic mice develop AD-like lesions secondary 
to the increased Th2 activity associated with expression of a constitutively active Stat6 
protein in T cells [14-17]. Approximately, 40-50% of these mice spontaneously develop AD-
like lesions due to increased Th2 responses, and disease correlates with decreased 
expression of barrier function genes [14, 16]. Thus, as in patients [18], reduced filaggrin 
expression in Stat6VT mice is attributed to increased Th2 activity leading to decreased 
expression of barrier function genes.
In AD patients, reduced filaggrin expression could result either from mutations in the 
filaggrin gene (FLG) or from the effects of Th2 cytokines [6, 18]. However, it is not clear if 
altered barrier function and increased Th2 activity function independently in the 
development of AD-like symptoms. The aim of the present study was to ascertain how 
altered barrier function as a result of the Ft mutations concomitant with increased pro-
allergic activity affected the development of AD-like disease.
RESULTS AND DISCUSSION
Ft mutation increases incidence and severity of allergic skin inflammation in Stat6VT mice
To determine the effect of Ft mutations in Stat6VT mice, we crossed Stat6VT transgenic and 
Ft mice. For simplicity, we refer to mice that are homozygous or heterozygous for the Ft 
mutations as Ft−/− and Ft+/−, respectively. Ft+/− skin has Flg protein expression that is 
intermediate between WT and Ft−/− skin [9]. WT, Stat6VT, Ft+/−, Ft−/−, Stat6VTxFt+/− 
and Stat6VTxFt−/− mice were monitored for the development of AD-like lesions. By 3-5 
months of age, Stat6VTxFt−/− mice developed severe allergic skin inflammation, 
characterized by erythema, scaling and crusting of lesions on the face and body (Fig 1A-C), 
in contrast to Stat6VT mice where only blepharitis was apparent at this time and skin lesions 
did not develop until later (6-7 months) (Fig. 1B-C). Unlike Stat6VT and Stat6VTxFt−/− 
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mice, Ft+/− or Ft−/− mice exhibited variable development of blepharitis and dry scaly skin, 
but no other manifestations of AD-like inflammation (Fig 1B). In previous reports, 
spontaneous skin inflammation was observed in older Ft−/− mice on a B6 genetic 
background [12]. Stat6VT transgenic mice with one or two Ft alleles also had an increased 
frequency of severe AD-like disease (Fig. 1B). We further observed a significantly higher 
percentage of Stat6VT and Stat6VT x Ft−/− mice requiring euthanasia due to severe disease, 
compared with WT or Ft−/− mice (Fig 1D). Although there was a trend for increased 
morbidity in the Stat6VT x Ft−/− mice compared with the Stat6VT mice, the difference was 
not significant. Our results demonstrate that the Ft mutation results in an earlier onset, higher 
incidence and increased severity of development of AD-like lesions in Stat6VT mice.
Exacerbated skin pathology and decreased barrier function in Stat6VT x Ft−/− mice
To further characterize the histopathology associated with increased disease in Stat6VT x Ft
−/− mice, we performed histological analysis of ear skin tissue from WT, Ft−/−, Stat6VT 
and Stat6VT x Ft−/− mice aged 3-5 months. We observed a thickening of the epidermis and 
dermis with infiltration of inflammatory cells in Stat6VT mice as previously described [14], 
that was further exacerbated in Stat6VT x Ft−/− mice with more severe inflammatory 
infiltrates than Stat6VT mice (Fig 2A). Infiltrates in Stat6VT skin include increases in T 
cells, eosinophils, mast cells, but no increases in type 2 innate lymphoid cells ([14, 19] and 
data not shown). Changes in the pathology of skin from Ft−/− mice compared with WT mice 
were minimal (Fig. 2A).
Although the Ft mutant decreases Flg expression below that observed in Stat6VT transgenic 
mice, it is not clear how much of an effect there is on the expression of other EDC genes. 
Quantitative PCR indicated a further reduction in the expression of Ivl and Hrnr in 
Stat6VTxFt−/− mice as compared with Stat6VT mice (Fig, 2B). The expression of Flg in 
Stat6VTxFt−/− mice was similar to that of Ft−/− mice, but the expression of Hrnr and Ivl 
were further decreased in Stat6VTxFt−/− mice as compared with Ft−/− mice. To verify the 
results with protein expression, we performed Flg immunoblots with skin from WT, Ft−/−, 
and Stat6VT transgenic mice. We observed the fully processed Flg protein at 32 kDa in the 
WT but not the Ft−/− samples, and not in the Stat6VT transgenic samples (Fig. 2C), 
consistent with previous results [8, 9, 14]. We did observe decreased expression of higher 
molecular weight unprocessed Flg proteins, also consistent with previous results [9]. The 
accumulated density for all bands in each lane was measured and averaged across multiple 
samples (Fig. 2D).
To determine if the decreased expression of epidermal barrier genes in mice had functional 
consequences, we tested the ability of the protein antigen to cross the skin and be taken up 
by dendritic cells as described earlier [14, 17]. Twenty-four hours after applying Alexa647-
labeled OVA to the shaved backs of WT, Stat6VT, Ft−/− and Stat6VTxFt−/− mice, dendritic 
cells (CD11c+ MHC II-hi cells that would include both Langerhans cells and dermal 
dendritic cells) in the draining lymph nodes were examined for the uptake of labeled OVA. 
Although we observed an increase in the percentage of Alexa647+ CD11c+ cells in Stat6VT 
mice compared with WT mice, the percentages of Alexa647+ CD11c+ cells in Stat6VTxFt−/
− mice were further increased compared with WT mice, Stat6VT or Ft−/− mice (Fig 2E). 
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These results indicate that in Stat6VT x Ft−/− transgenic mice, there is increased protein 
translocation across the skin barrier.
It is interesting that protein translocation was not increased in Ft−/− mice as previous reports 
showed increased cutaneous sensitization in Ft−/− and Flg−/− mice [8, 12]. Notably, these 
earlier studies utilized repeated allergen applications where a Th2 response developed, 
whereas the experiment described here (Fig. 2E) is based on a short-term 24-hour assay 
where endogenous cytokine responses would not likely develop. These differences suggest a 
requirement for an ongoing Th2 response to facilitate increased protein translocation. This 
interpretation is consistent with acute protein translocation being increased in Stat6VT 
transgenic mice, where a Th2 cytokine milieu is present, and even more pronounced when 
combined with Ft mutations. As Ft−/− mice do develop Th2 responses following 
sensitization, it would be interesting to assess the effect of Stat6-deficiency on AD like 
lesions in the Ft−/− mice. Our results suggest that the two genetic lesions causing decreased 
barrier function and increased Th2 activity work independently and cooperatively in the 
development of AD-like disease. Although the increased Th2 activity in the Stat6VT mice 
decreases EDC and other skin barrier function gene expression, we speculate that the 
mutations in the Ft mice result in earlier impairment of barrier function in Stat6VT 
transgenic mice that contribute to the earlier initiation of disease.
CONCLUDING REMARKS
In the present report, we demonstrate that the mutations in the Ft mice that result in 
decreased barrier function exacerbate the development of spontaneous allergic skin disease 
in Stat6VT mice. This is consistent with the increased propensity of Ft mice, and mice with 
specific mutations in Flg and Tmem79, to develop AD-like lesions following sensitization 
[8, 10, 11]. Our results are also consistent with human studies where FLG mutations that are 
neither required nor sufficient for disease, are strong predisposing factors for AD, 
highlighting the idea that changes in barrier function alone are not sufficient to generate a 
severe and high frequency early-onset disease [6, 7]. As therapies develop to block Th2 
responses in AD, it will be interesting to compare the effects of treatment on patients with or 
without genetic mutations in barrier function genes [20].
MATERIALS AND METHODS
Generation of Stat6VT and Stat6VT x Ft−/− mice
The generation of Stat6VT transgenic mice on a C57BL/6 background was previously 
described [14, 15]. Transgene-positive founders (CD2: Stat6VT [78] line), where the human 
Stat6 gene with V547 and T548 mutated to alanine is under transcriptional control of the 
CD2 locus control region, were backcrossed to C57BL/6 mice (Harlan Breeders, 
Indianapolis, IN). To obtain Stat6VT mice with barrier function mutations, Stat6VT mice 
were mated to Flaky tail mice that were obtained from Dr. John Sundberg at the Jackson 
Laboratory (Bar Harbor, ME). All mice were maintained in specific pathogen-free 
conditions, and experiments were approved by the Indiana University Institutional Animal 
Care and Use Committee.
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Quantification of incidence and mortality in Stat6VT, Stat6VT x and Stat6VT x Ft−/− mice
Mice were monitored for the onset and development of AD lesions between 3-13 months. 
The percentage of mice that develop no disease, blepharitis, dry flaky skin or severe AD 
lesions was determined. Kaplan-Meier morbidity estimates were used to evaluate the mice 
that required euthanasia or those that died due to severe lesions and analysis was performed 
with GraphPad Prism 6. For other analyses, data were expressed as means of 3 independent 
experiments and analyzed with the Student t-test or Chi-square test. A p value of less than 
0.05 was considered statistically significant.
Histological examination of skin sections
Skin tissues were fixed in neutral buffered Formalin. Paraffin-embedded tissue sections were 
stained with hematoxylin and eosin (H & E) to evaluate the infiltration of inflammatory 
cells, by light microscopy. Filaggrin protein expression was analyzed as previously 
described [19].
Isolation of RNA from skin and real-time PCR
For real-time PCR measurements, the skin was homogenized in a tissue lyser (Qiagen, 
Valencia, CA), and RNA isolated with the RNeasy fibrous tissue kit (Qiagen) was used to 
synthesize cDNA with the First-Strand Cloned AMV kit (Invitrogen, Rockville, MD). 
Message levels of barrier function genes were determined by Taqman assay (Applied 
Biosystems, Foster City, CA). Cycle number of the samples was normalized to the 
expression of β2- microglobulin.
Epicutaneous allergen exposure and skin dendritic cell migration to draining lymph nodes
Mice were epicutaneously exposed to OVA-Alexa Fluor 647 (Invitrogen, Carlsbad, CA). 
Briefly, the back skin of anesthetized mice was shaven and tape stripped three times before 
painting with 500 μg OVA-Alexa Fluor 647 dissolved in PBS. Twenty-four hours later, mice 
were sacrificed and draining lymph nodes were harvested. Cells were first incubated with 
anti-CD16/CD32 mAb (2.4G2; BD Biosciences, San Jose, CA) and stained with FITC anti-
mouse MHC class II (MHC-II) and PE anti-mouse CD11c (BD Biosciences). The proportion 
of OVA-Alexa Flour 647+ cells was quantified as described previously by gating on CD11c+ 
MHC II-hi cells [14].
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Figure 1. 
Stat6VT mice with Flaky tail mutations develop severe allergic skin inflammation. (A) 
Photographs of WT, Stat6VT, Flaky tail (Ft−/−) and Stat6VTxFt−/− mice. B, Percent of 
mice that develop no disease, blepharitis, dry flaky skin or AD lesions is shown. Data were 
analyzed by Chi-square test, ** p < 0.0001, n=7-18. C, Age of onset of severe disease in 
Stat6VT and Stat6VTxFt−/− mice. Data are mean ± SEM (n=7-17 mice/group) and are 
pooled from 2-3 independent experiments. ** p < 0.01; Student’s t-test. D, Morbidity curves 
of the indicated genotypes by Kaplan-Meier analysis is shown. Data shown are pooled from 
2-3 independent experiments; n=8-17 per group, and data were analyzed by Chi-square test.
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Figure 2. 
Stat6VTxFt−/− mice have severe skin immunopathology and decreased barrier function. A, 
Histological analysis of ear tissue from the indicated mice (n= 5-10 mice/group). Samples 
were fixed and stained with H & E, and images were taken at x100 (WT, Ft−/−and left 
panels for Stat6VT and Stat6VT x Ft−/−) or x600 (right panels for Stat6VT and Stat6VT x 
Ft−/−). Black bars = 1 mm. Blue bars = 0.1 mm. Boxes indicate regions enlarged in 
photomicrograph to the right. B, Expression of EDC genes. RNA was isolated from the ear 
skin of mice and expression of Flg, Hrnr, and Ivl determined by quantitative PCR, Data are 
mean ± SEM of 2-4 mice and are representative of three independent experiments. * p < 
0.05; Student’s t-test,. C, Immunoblot of filaggrin expression in skin samples from the 
indicated genotypes. Representative of three samples from separate mice on one 
immunoblot. D, Averages of densitometry for replicate samples of filaggrin expression 
relative to actin expression. E, Ft mutations in Stat6VT transgenic mice further decrease the 
barrier function. Mice from the indicated genotypes were treated with OVA-Alexa 647 and 
uptake by DCs was measured as described in methods. (D and E) Bar graphs represent the 
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mean ± SEM (n= 3-5 mice /group) and are representative of two independent experiments. 
*p < 0.05, ** p < 0.01; Student’s I-test.
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